Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Otolaryngology (Ear, Nose, Throat) | Family Medicine
Clinical Trials: Head and Neck Cancer
A listing of clinical trials currently looking for volunteers to enroll in Head and Neck Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham (UAB)
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
View More »
Birmingham : University of Alabama at Birmingham
Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
Birmingham : University of Alabama at Birmingham
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
Arizona
California
Escondido : Southwest Cancer Care
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Monterey : Monterey Bay Oncology
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Oxnard : Ventura County Hematology Oncology Specialists
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Pleasant Hill : Bay Area Cancer Research, LLC
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
View More »
Alhambra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Bakersfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Fullerton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Northridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Redondo Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Stanford :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Stanford : Stanford University School of Medicine
Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer
Stanford : Stanford Cancer Center
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Colorado
Aurora : University of Colorado Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Denver : Eastern Colorado Health Care System - Denver VA
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
View More »
Aurora :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Aurora : University of Colorado Cancer Center
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Grand Junction : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
District of Columbia
Washington : George Washington University - Medical Faculty Associates
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Washington : Georgetown University Medical Center
Lapatinib and Cetuximab in Patients With Solid Tumors
Florida
Holiday : Pasco Pinellas Cancer Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Jacksonville : Integrated Community Oncology Network
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Miami : Advanced Medical Specialties
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
New Port Richey : Pasco Pinellas Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Tampa : H. Lee Moffitt Cancer Center & Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Miami :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Weston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Georgia
Illinois
Elgin : Sherman Health
ECOG E1305 A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer
Elgin : Sherman Health
RETAIN: Resistance Training and Physical Functioning in Patients with Head & Neck Cancer
View More »
Chicago : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Chicago :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Chicago : The University of Chicago Medical Center
Everolimus Versus Placebo in Head and Neck Cancer
Chicago : The University of Chicago Medical Center
Randomized Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Indiana
Kansas
Kentucky
Paducah :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Louisiana
Shreveport : Louisianna State University
Everolimus Versus Placebo in Head and Neck Cancer
Shreveport : Overton Brooks VA Medical Center
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Maryland
Bethesda : Center for Cancer and Blood Disorders
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Baltimore : Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in NNSCC
Baltimore :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Massachusetts
Michigan
Mississippi
Missouri
Bridgeton : Saint Louis Cancer Care LLP
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
St. Louis : Washington University
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
View More »
St Joseph :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Nebraska
Nevada
New Hampshire
New Jersey
East Orange : NJ Medical School VA NJ Healthcare
Squamous Cell Carcinoma
View More »
Basking Ridge : Memorial Sloan-Kettering Cancer Center at Basking Ridge
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Basking Ridge : Memorial Sloan-Kettering Cancer Center at Basking Ridge
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
New Mexico
Albuquerque : University of New Mexico Cancer Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
New York
Bronx : Montefiore Medical Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Buffalo : Roswell Park Cancer Institute
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Latham : New York Oncology, Hematology
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Manhasset : Biomedical Research Alliance of New York
Head and Neck Cancer - Adults
New York : University of Colorado - Denver
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
New York : Columbia University
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
New York : Beth Israel Medical Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
View More »
Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Commack : Memorial Sloan-Kettering Cancer Center at Commack
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
New York : Memorial Sloan Kettering Cancer Center
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
New York : Memorial Sloan Kettering Cancer Center
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
New York : Memorial Sloan Kettering Cancer Center
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Rockville Centre : Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
North Carolina
Durham : Duke University
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Chapel Hill : University of North Carolina at Chapel Hill
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Chapel Hill : The University of North Carolina at Chapel Hill
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
Winston-Salem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Ohio
Oregon
Pennsylvania
Philadelphia : University of Pennsylvania
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Pittsburgh : University of Pittsburgh Medical Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
View More »
Philadelphia : Fox Chase Cancer Center
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Philadelphia : Thomas Jefferson University
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
South Carolina
Tennessee
Nashville : Sarah Cannon Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Knoxville :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Nashville : Vanderbilt University
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Nashville : Vanderbilt-Ingram Cancer Center
Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
Texas
Austin : Texas Oncology – South Austin
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Dallas : Texas Oncology - Baylor - Charles A. Sammons Cancer Center
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Dallas : Mary Crowley Cancer Research Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Abilene : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Arlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Ft. Worth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Houston : Baylor College of Medicine
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
Houston : UT MD Anderson Cancer Center
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Virginia
Washington
West Virginia
Australia
Kurralta Park :
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Canada
Barrie : Royal Victoria Regional Health Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Edmonton : Cross Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Greenfield Park : Hôpital Charles-LeMoyne
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Laval : Cité de la Santé de Laval
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
London : London Regional Cancer Program
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
London : London Health Sciences Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Montreal : Jewish General Hospital
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Montreal : Maisonneuve-Rosemont Hospital Research Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Sherbrooke : CHUS Hôpital Fleurimont
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
Sudbury : Northeast Cancer Centre of Health Sciences North, Health Sciences North
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Thunder Bay : Thunder Bay Regional Health Sciences Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Toronto, Ontario : Princess Margaret Hospital
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Vancouver : British Columbia Cancer Agency - Vancouver Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Winnipeg : Cancer Care Manitoba Updated
A Phase 1/2 study of PX-866 and docetaxel in patients with solid tumors
View More »
Calgary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Edmonton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
London : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Montreal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Ottawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Toronto : Princess Margaret Hospital
A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer
Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Finland
Helsinki : Department of Oncology, Helsinki University Central Hospital
Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer
Germany
Germany : University of Heidelberg Medical Center
Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)
Korea, Republic of
Jung-gu Daejeon : Chungnam National University Hospital
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Mexico
Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Merida : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Mitras Norte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Head and Neck Cancer
Netherlands
Amsterdam : Netherlands Cancer Institute
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
Nijmegen : University Medical Center Nijmegen st Radboud
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
United Kingdom
Papworth Everard : Papworth Hospital NHS Trust
Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib
